TABLE 5.

Summary of clinical research data on second-line or above therapy for advanced or metastatic gastric cancer.

Study	Patients	Cohort	Treatment line	ORR	DCR	Median PFS	Median OS
WJOG 4007	Metastatic or recurrent gastric adenocarcinoma	Paclitaxel	Second-line	—	—	3.6 (3.3–3.8)	9.5 (8.4–10.7)
WJOG 4007	Metastatic or recurrent gastric adenocarcinoma	Irinotecan	Second-line	—	—	2.3 (2.2–3.1)	8.4 (7.6–9.8)
Eliza Hawkes,2011	Oesophagogastric cancer	Docetaxel + irinotecan	Second-line	24.4%	41.5%	11 weeks (9–13)	24 weeks (12–35)
RAINBOW	Advanced gastric or GEJ	Ramucirumab plus paclitaxel vs. placebo plus paclitaxel	Second-line	27.9 vs. 16.1%	80.0 vs. 63.6%	4.4 (4.2–5.3) vs. 2.9 (2.8–3.0)	9.6 (8.5–10.8) vs. 7.4 (6.3–8.4)
RAINBOW-Asia	Metastatic or locally advanced gastric or GEJ	Ramucirumab plus paclitaxel vs. placebo plus paclitaxel	Second-line	26.5 vs. 20.5%	76.8 vs. 71.2%	4.14 (3.71–4.30) vs. 3.15 (2.83–4.14)	8.71 (7.98–9.49) vs. 7.92 (6.31–9.10)
Jin Li,2016	Advanced gastric or GEJ	Apatinib vs. placebo	Third or above	2.84% vs. 0	42.05% vs. 8.79%	2.6 (2.0–2.9) vs. 1.8 (1.4–1.9)	6.5 (4.8–7.6) vs. 4.7 (3.6–5.4)
ATTRACTION-02	Advanced or recurrent gastric or GEJ	Nivolumab or placebo	Third or above	11.2% vs. 0	40.3% vs. 25%	1.61 (1.54–2.30) vs. 1.45 (1.45–1.54)	5.26 (4.60–6.37) vs. 4.14 (3.42–4.86)
KEYNOTE-059	Metastatic gastric or GEJ	Pembrolizumab	Third or above	11.6%	27.0%	2.0 (2.0–2.1)	5.6 (4.3–6.9)